Gender Effects of Single Nucleotide Polymorphisms and MiRNAs Targeting Clock-genes in Metastatic Colorectal Cancer Patients (mCRC)

Overview

Journal Sci Rep

Specialty Science

Date 2016 Sep 27

PMID 27666868

Citations 11

Authors

Carlo Garufi

Elisa Giacomini

Angela Torsello

Isabella Sperduti

Elisa Melucci

Marcella Mottolese

Massimo Zeuli

Giuseppe Maria Ettorre

Teresa Ricciardi

Francesco Cognetti

Mauro Magnani

Annamaria Ruzzo

Affiliations

Soon will be listed here.

Abstract

The circadian system is composed of a set of clock-genes including PERIOD, CLOCK, BMAL1 and CRY. Disrupting this system promotes cancer development and progression. The expression levels of miR-206, miR-219, miR-192, miR-194 and miR-132 regulating clock-genes and three functional polymorphisms rs11133373 C/G, rs1801260 T/C, rs11133391 T/C in CLOCK sequence were associated with the survival of 83 mCRC patients (50 males and 33 females). Longer overall survival (OS) was observed in women compared to men, 50 versus 31 months. This difference was associated with rs11133373 C/C genotype (p = 0.01), rs1801260 T/C+C/C genotype (p = 0.06) and rs11133391 T/T genotype (p = 0.06). Moreover women expressing high levels (H) of miR-192 (p = 0.03), miR-206 (p = 0.003), miR-194 (p = 0.02) and miR-219 (p = 0.002) had a longer OS compared to men. In women longer OS was reinforced by the simultaneous presence of two or more H-miR, 58 months versus 15 months (p = 0.0008); in this group of women an OS of 87 months was reached with the additional presence of rs11133391T/T genotype (p = 0.02). In this study we identified a subgroup of female patients who seems to have a better prognosis. Personalized medicine should prospectively take into account both genetic and gender differences.

Citing Articles

Psychological Interventions for Insomnia in Patients with Cancer: A Scoping Review.

Gonzalez A, Jimenez-Torres G, De Moraes A, Geng Y, Pawate V, Khan R Cancers (Basel). 2024; 16(22).

PMID: 39594805 PMC: 11593114. DOI: 10.3390/cancers16223850.

MicroRNAs as Potential Orchestrators of Alzheimer's Disease-Related Pathologies: Insights on Current Status and Future Possibilities.

Abuelezz N, Nasr F, AbdulKader M, Bassiouny A, Zaky A Front Aging Neurosci. 2021; 13:743573.

PMID: 34712129 PMC: 8546247. DOI: 10.3389/fnagi.2021.743573.

Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer.

Aroca-Siendones M, Moreno-SanJuan S, Puentes-Pardo J, Verbeni M, Arnedo J, Escudero-Feliu J Biomedicines. 2021; 9(8).

PMID: 34440171 PMC: 8391187. DOI: 10.3390/biomedicines9080967.

NOTCH Single Nucleotide Polymorphisms in the Predisposition of Breast and Colorectal Cancers in Saudi Patients.

Alanazi I, Shaik J, Reddy Parine N, Al Naeem A, Azzam N, Almadi M Pathol Oncol Res. 2021; 27:616204.

PMID: 34257585 PMC: 8262141. DOI: 10.3389/pore.2021.616204.

Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity.

Haupt S, Haupt Y Front Genet. 2021; 12:632719.

PMID: 33664771 PMC: 7920968. DOI: 10.3389/fgene.2021.632719.

References

Smith R, Colangelo L, Wieand H, Begovic M, Wolmark N . Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst. 2004; 96(15):1128-32. DOI: 10.1093/jnci/djh220. View

Barford A, Dorling D, Davey Smith G, Shaw M . Life expectancy: women now on top everywhere. BMJ. 2006; 332(7545):808. PMC: 1432200. DOI: 10.1136/bmj.332.7545.808. View

Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M . Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment.... J Clin Oncol. 2006; 24(22):3562-9. DOI: 10.1200/JCO.2006.06.1440. View

Cheng H, Papp J, Varlamova O, Dziema H, Russell B, Curfman J . microRNA modulation of circadian-clock period and entrainment. Neuron. 2007; 54(5):813-29. PMC: 2590749. DOI: 10.1016/j.neuron.2007.05.017. View

Hawkins G, Meyers D, Bleecker E, Pack A . Identification of coding polymorphisms in human circadian rhythm genes PER1, PER2, PER3, CLOCK, ARNTL, CRY1, CRY2 and TIMELESS in a multi-ethnic screening panel. DNA Seq. 2007; 19(1):44-9. DOI: 10.1080/10425170701322197. View

Press O, Zhang W, Gordon M, Yang D, Lurje G, Iqbal S . Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res. 2008; 68(8):3037-42. DOI: 10.1158/0008-5472.CAN-07-2718. View

Ciarleglio C, Ryckman K, Servick S, Hida A, Robbins S, Wells N . Genetic differences in human circadian clock genes among worldwide populations. J Biol Rhythms. 2008; 23(4):330-40. PMC: 2579796. DOI: 10.1177/0748730408320284. View

Nagel R, Clijsters L, Agami R . The miRNA-192/194 cluster regulates the Period gene family and the circadian clock. FEBS J. 2009; 276(19):5447-55. DOI: 10.1111/j.1742-4658.2009.07229.x. View

Zhu Y, Stevens R, Hoffman A, FitzGerald L, Kwon E, Ostrander E . Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 2009; 69(24):9315-22. PMC: 2955869. DOI: 10.1158/0008-5472.CAN-09-0648. View

10.

Hoffman A, Yi C, Zheng T, Stevens R, Leaderer D, Zhang Y . CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res. 2010; 70(4):1459-68. PMC: 3188957. DOI: 10.1158/0008-5472.CAN-09-3798. View

11.

Press O, Zhang W, Gordon M, Yang D, Haiman C, Azuma M . Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer. Pharmacogenomics J. 2010; 11(5):375-82. PMC: 2941547. DOI: 10.1038/tpj.2010.45. View

12.

Innominato P, Levi F, Bjarnason G . Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev. 2010; 62(9-10):979-1001. DOI: 10.1016/j.addr.2010.06.002. View

13.

Garufi C, Torsello A, Tumolo S, Ettorre G, Zeuli M, Campanella C . Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010; 103(10):1542-7. PMC: 2990583. DOI: 10.1038/sj.bjc.6605940. View

14.

Alvarez-Saavedra M, Antoun G, Yanagiya A, Oliva-Hernandez R, Cornejo-Palma D, Perez-Iratxeta C . miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet. 2010; 20(4):731-51. PMC: 3115667. DOI: 10.1093/hmg/ddq519. View

15.

Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont A, Holzel D . Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2010; 131(3):719-26. DOI: 10.1038/jid.2010.354. View

16.

Gordon M, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F . Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics. 2010; 12(1):27-39. PMC: 3836679. DOI: 10.2217/pgs.10.163. View

17.

Yu E, Weaver D . Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging (Albany NY). 2011; 3(5):479-93. PMC: 3156599. DOI: 10.18632/aging.100323. View

18.

Cook M, McGlynn K, Devesa S, Freedman N, Anderson W . Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1629-37. PMC: 3153584. DOI: 10.1158/1055-9965.EPI-11-0246. View

19.

Zhou F, He X, Liu H, Zhu Y, Jin T, Chen C . Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer. Cancer. 2011; 118(4):937-46. DOI: 10.1002/cncr.26348. View

20.

Zhou W, Li Y, Wang X, Wu L, Wang Y . MiR-206-mediated dynamic mechanism of the mammalian circadian clock. BMC Syst Biol. 2011; 5:141. PMC: 3201034. DOI: 10.1186/1752-0509-5-141. View